September 17, 2025 — Today at EASD, investigators for the ATTAIN-1 pivotal phase three trial are presenting detailed results for orforglipron in obesity. These results, published yesterday in the New England Journal of Medicine, offer no big surprises. The effectiveness in this 72-week trial was acceptable. But a big question hangs in the air. Will orforglipron be the GLP-1 […]
September 12, 2024 — The obesity buzz of the day at EASD annual meeting is clearly amycretin. Amycretin is a new oral medication under study for obesity that activates both GLP-1 and amylin receptors. The excitement came because this is the first public presentation of clinical data on amycretin. This news is impressive on two counts. First, the dosage […]
October 6, 2023 — At EASD this week, it was quite a showing for tirzepatide. Sold under the brand name Mounjaro, it’s already available for treating diabetes and it’s awaiting approval for treating obesity. Based on the research presented at EASD this week, semaglutide might be looking a little like old news. For tirzepatide, a total of 11 presentations […]
